WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H562002
CAS#: 1222810-74-3
Description: VU591 is the first reported selective, small-molecule ROMK inhibitor. It inhibits potassium transport in isolated perfused rat collecting duct tubules with no effect on sodium transport.
Hodoodo Cat#: H562002
Name: VU591
CAS#: 1222810-74-3
Chemical Formula: C16H12N6O5
Exact Mass: 368.09
Molecular Weight: 368.300
Elemental Analysis: C, 52.18; H, 3.28; N, 22.82; O, 21.72
Synonym: VU591; VU-591; VU 591;
IUPAC/Chemical Name: 2,2'-(oxybis(methylene))bis(5-nitro-1H-benzo[d]imidazole)
InChi Key: ZQPXNYLXYNRFNP-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H12N6O5/c23-21(24)9-1-3-11-13(5-9)19-15(17-11)7-27-8-16-18-12-4-2-10(22(25)26)6-14(12)20-16/h1-6H,7-8H2,(H,17,19)(H,18,20)
SMILES Code: O=[N+](C1=CC2=C(C=C1)NC(COCC3=NC(C=C([N+]([O-])=O)C=C4)=C4N3)=N2)[O-]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 368.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Horng JL, Yu LL, Liu ST, Chen PY, Lin LY. Potassium Regulation in Medaka (Oryzias latipes) Larvae Acclimated to Fresh Water: Passive Uptake and Active Secretion by the Skin Cells. Sci Rep. 2017 Nov 24;7(1):16215. doi: 10.1038/s41598-017-16381-7. PubMed PMID: 29176723; PubMed Central PMCID: PMC5701230.
2: Kharade SV, Flores D, Lindsley CW, Satlin LM, Denton JS. ROMK inhibitor actions in the nephron probed with diuretics. Am J Physiol Renal Physiol. 2016 Apr 15;310(8):F732-F737. doi: 10.1152/ajprenal.00423.2015. Epub 2015 Dec 9. PubMed PMID: 26661652; PubMed Central PMCID: PMC4835929.
3: Swale DR, Sheehan JH, Banerjee S, Husni AS, Nguyen TT, Meiler J, Denton JS. Computational and functional analyses of a small-molecule binding site in ROMK. Biophys J. 2015 Mar 10;108(5):1094-103. doi: 10.1016/j.bpj.2015.01.022. PubMed PMID: 25762321; PubMed Central PMCID: PMC4375722.
4: Bhave G, Chauder BA, Liu W, Dawson ES, Kadakia R, Nguyen TT, Lewis LM, Meiler J, Weaver CD, Satlin LM, Lindsley CW, Denton JS. Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel. Mol Pharmacol. 2011 Jan;79(1):42-50. doi: 10.1124/mol.110.066928. Epub 2010 Oct 6. PubMed PMID: 20926757; PubMed Central PMCID: PMC3014278.
